The Role of hCG in Thawed Embryo Transfer

NCT07004192 | Recruiting Phase 4 FDA Drug

• 1 other identifier: FCLV 2025-1
• Study Type: interventional
• Target: 220
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Conditions

Infertility (IVF Patients)

Keywords

Thawed embryo transfer

Outcome Measures

Primary Outcomes (1)

• Blood pressure

  Mean arterial pressure measured in third trimester of pregnancy

  Third trimester of pregnancy

Study Arms (2)

hCG Group

EXPERIMENTAL

This group receives one injection of hCG.

Drug: HCG injection

No hCG Group

ACTIVE COMPARATOR

This arm receives no hCG.

Other: No intervention

Interventions

HCG injection DRUG

5000 IU hCG injection

hCG Group

No intervention OTHER

No hCG administered in this group.

No hCG Group

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female adult expecting to receive transfer of a thawed embryo.
• At least one available frozen blastocyst of transferrable quality.
• Non-menopausal female with at least one antral follicle.
• Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
• Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

You may not qualify if:

• Minors (age\<18 years).
• Use of embryo(s) frozen at another center.
• Patient insistent on transfer of two embryos.
• Patient or partner unable to provide informed consent in English.
• Patient already enrolled in any other research study for her embryo transfer.
• History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy.
• Patient for whom the physician assesses this protocol is inappropriate or unsafe.

Sponsors & Collaborators

• Fertility Center of Las Vegas: lead

Study Sites (1)

Fertility Center of Las Vegas

Las Vegas, Nevada, 89113, United States

RECRUITING

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Central Study Contacts

Shironda Research Assistant

CONTACT

702-254-1777; shironda@fertilitycenterlv.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Director

Study Record Dates

• First Submitted: May 27, 2025
• First Posted: June 4, 2025
• Study Start: June 2, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: July 1, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)